Worldwide treatment of hepatitis C could be within sight at the right cost

February 23, 2015
Worldwide treatment of hepatitis C could be within sight at the right cost
A 12-week course of the new drug sofosbuvir in the US is priced at as much as $84,000 per person

Lowering the cost of hepatitis C drugs is possible and key to achieving global access to treatment, according to new research by the University of Liverpool and Imperial College London.

There are an estimated 185 million people infected with the hepatitis C virus worldwide and 160,000 in Britain. Currently there is no vaccine and, if left untreated, infection can lead to cirrhosis and liver cancer, causing up to 500,000 related deaths globally per year.

Hepatitis C is particularly problematic in low to ; for example 12 million people are infected in Egypt.

A new and effective generation of direct-acting (DAAs) has been developed to treat hepatitis C. However, at present these drugs are highly expensive. A 12-week course of the new drug sofosbuvir in the US is priced at as much as $84,000 per person and £55,440 in the UK. The NHS has recently delayed introduction of sofosbuvir due to its high price.

The treatment of HIV provides a precedent for cutting the costs of drugs on a large scale to make them available across the world. The drugs that have been rolled out worldwide for HIV are similar in chemical structure and mechanisms to the new generation of hepatitis C drugs.

Monitoring costs

Researchers at Liverpool believe that it is feasible that global hepatitis C treatment could be achieved if the manufacturing and monitoring of costs of those drugs were minimised in the same way as with HIV treatments, which involved the lifting of patents to allow drugs to be made by generic manufacturers.

In the study, published in Hepatology, the researchers used HIV drugs as a framework for the analysis to explore what would be possible if drugs were produced at a large scale with the removal of patents to enable generic versions of these DAAs to be manufactured. This is feasible since India has recently filed a patent opposition to sofosbuvir and, if successful, this would mean the patent would no longer restrict the manufacture of the and could be made by a range of manufacturers.

By taking a bottom-up approach using information on the drugs' raw materials, molecular structure and doses, the researchers estimated that if production was done at a large enough scale, it may be possible to dramatically reduce the cost of these news drugs. The study estimated that to treat at least five million people with a combination of the two DAAs sofosbuvir and daclatasvir could cost $122 per person.

Bringing down the price

Co-author, Dr Andrew Hill, from the University of Liverpool's Institute of Translational Medicine, said: "As hepatitis C drugs are so similar to those used to treat HIV we assumed they have the potential to be made in the same way; producing the drugs at economies of scale in large factories and within a freely competitive market where patents have been lifted to allow generic production.

"We know from the experience of HIV treatment that charitable funders want to be able to donate a large sum of money and know it will treat a large amount of people. Our results indicate that this is possible by bringing down the price of hepatitis C drugs for a set target for the number treated."

Through a review of clinical trials, the study identified the four most effective combination regimes of DAAs for a 12-week treatment course for Hepatitis C. The study estimated the minimum costs of treatment by this new generation of DAAs, assuming large scale manufacture to treat at least five million patients per year, in a freely competitive market without the limitations of current patents. The analysis involved going back to the basic chemistry of the drugs to ascertain the cost of the raw materials, synthesis and manufacture of the drugs.

Barriers

Dr Graham Cooke, from the Department of Medicine at Imperial College London, said: "We now have treatments to deal with C, but there are operational, legal and political barriers preventing us from ensuring access for people on a global and national scale.

"To break down these barriers, we need to learn lessons from the large-scale rollout of HIV treatment and accelerate the process. In this study we have estimated the possible reduction in cost of these new drugs if some of these barriers are removed and they can be produced at a large scale with free competition and improved production efficiency. "

The results showed that the combination of sofosbuvir and daclatasvir to treat five million people could potentially cost $122 per person. These two drugs are already licensed and considered to be the most promising for large-scale programmes.

Explore further: WHO urges global push to treat hepatitis C (Update)

More information: van de Ven, N., Fortunak, J., Simmons, B., Ford, N., Cooke, G. S., Khoo, S. and Hill, A. (2015), "Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus." Hepatology. doi: 10.1002/hep.27641

Related Stories

WHO urges global push to treat hepatitis C (Update)

April 9, 2014
The World Health Organization called Wednesday for a dramatic increase in screening and treatment of hepatitis C, saying higher demand would help drive down the cost of drugs for the disease.

French charity attacks Gilead patent for hepatitis drug

February 10, 2015
French charity Medecins du Monde (MdM) on Tuesday said it was contesting a European patent awarded to a hepatitis drug made by US firm Gilead Sciences, arguing the treatment was too costly.

Spain vows hepatitis C action after calls for new drugs

January 12, 2015
Spain's government Monday promised new measures to fight hepatitis C, following protests by patients who complained authorities were denying them the latest drugs to treat the deadly liver disease.

EASL publishes online recommendations on the management of hepatitis C

April 9, 2014
The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress (ILC). These EASL recommendations ...

Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's

January 16, 2015
Insurer Aetna has made new hepatitis C drugs from Gilead Sciences Inc. preferred treatments for customers with the liver-destroying virus.

High hepatitis C cure rate seen in NIH-led trial of six-week oral drug regimens

January 12, 2015
Thirty-eight of 40 volunteers with hepatitis C virus (HCV) infections who received a combination of three direct-acting oral drugs for six weeks were cured in a clinical trial conducted at the National Institutes of Health ...

Recommended for you

Scientists develop infection model for tickborne flaviviruses

August 22, 2017
National Institutes of Health (NIH) scientists have filled a research gap by developing a laboratory model to study ticks that transmit flaviviruses, such as Powassan virus. Powassan virus was implicated in the death of a ...

Zika virus stifles pregnant women's weakened immune system to harm baby, study finds

August 21, 2017
The Zika virus, linked to congenital birth defects and miscarriages, suppresses a pregnant woman's immune system, enabling the virus to spread and increasing the chances an unborn baby will be harmed, a Keck School of Medicine ...

Fatty liver can cause damage to other organs via crosstalk

August 21, 2017
Nonalcoholic fatty liver disease is increasingly common. Approximately every third adult in industrialized countries has a morbidly fatty liver. This not only increases the risk of chronic liver diseases such as liver cirrhosis ...

Novel approach to track HIV infection

August 18, 2017
Northwestern Medicine scientists have developed a novel method of tracking HIV infection, allowing the behavior of individual virions—infectious particles—to be connected to infectivity.

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.